Tonix Pharmaceutical Holding Corp.

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Tonix is a research and development company that is focused on identifying promising new product candidates and advancing them through clinical development toward regulatory approval.
Tonix is focused on developing small molecules and biologics for the treatment of CNS (pain, neurology, psychiatry, addiction) and immunological disorders (vaccines, immunosuppression, oncology, autoimmune).
TNX-102 SL: Currently in late stage clinical development (Phase 3, F304) for the treatment of fibromyalgia. Interim analysis anticipated September 2020 with topline results expected Q1 2021. F304 utilizes a higher dose (5.6 mg) than previous FM studies (2.6 mg), based on findings from trials conducted in posttraumatic stress disorder (PTSD) showing a dose response with a greater effect for the 5.6 mg dose. TNX-102 SL is also being developed for the treatment of posttraumatic stress disorder (PTSD), agitation in Alzheimer’s disease (AAD) and alcohol use disorder (AUD).
Ticker:
TNXP
Exchange:
NASDAQ
Company Type:
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
TNX-102 SL
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
8
Speaker
photo
Chief Executive Officer
Tonix Pharmaceuticals Holding Corp/.